Fortress Biotech, Inc.
FBIOPHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Part of the healthcare sector, Fortress Biotech, Inc. (FBIOP) is listed under Biotechnology. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squam.
Market Cap
—
Beta
1.21
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.86
EPS (Fwd)
—
ROE
109.8%
ROA
-13.0%
Cash
$255.8M
Total Debt
$53.6M
Free CF
$15.0M
52W Change
166.0%
Annual Financials
Cash vs Debt
Fortress Biotech, Inc. holds $255.8M in cash against $53.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $15.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 109.8% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $75.7M to $63.3M.
With cash comfortably exceeding debt, FBIOP has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Fortress Biotech, Inc. and its sector.